Restrictive cardiomyopathy: Difference between revisions
Ochuko Ajari (talk | contribs) |
Ochuko Ajari (talk | contribs) |
||
Line 24: | Line 24: | ||
{|style="width:80%; height:100px" border="1" | {|style="width:80%; height:100px" border="1" | ||
|style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular''' | |style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular''' | ||
|style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | | |style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | [[Amyloidosis]], [[carcinoid syndrome|carcinoid heart disease]], [[cardiac amyloidosis]], [[endocardial fibroelastosis]], [[endomyocardial fibrosis]], [[heart transplant]], [[hemochromatosis]], [[Hurler syndrome]], [[Noonan's syndrome]] | ||
|- | |- | ||
|bgcolor="LightSteelBlue"| '''Chemical/Poisoning''' | |bgcolor="LightSteelBlue"| '''Chemical/Poisoning''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[mercury|Mercurial agents]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 35: | Line 35: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Dermatologic''' | | '''Dermatologic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Scleroderma]], [[systemic sclerosis]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Drug Side Effect''' | | '''Drug Side Effect''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Anthracyclines]], [[busulfan]], [[chemotherapy]], [[drugs]], [[ergotamine]], [[hydroxychloroquine]], [[methysergide]], [[serotonin]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 47: | Line 47: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Endocrine''' | | '''Endocrine''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Amyloidosis]], [[carcinoid syndrome]], [[carcinoid tumors]], [[diabetes mellitus]], [[carcinoid syndrome|carcinoid heart disease]], [[hemochromatosis]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 55: | Line 55: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Gastroenterologic''' | | '''Gastroenterologic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Alpha-L-iduronidase deficiency]], [[glycogen storage disease]], [[hemochromatosis]], [[Hurler syndrome]], [[sarcoidosis]], [[carcinoid syndrome|carcinoid heart disease]], [[carcinoid syndrome]], [[scleroderma]], [[systemic sclerosis]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Genetic''' | | '''Genetic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Alpha-L-iduronidase deficiency]], [[Anderson-Fabry disease]], [[cystinosis]], [[desminopathy]], [[Fabry's disease]], [[familial]], [[Gaucher's disease]], [[hemochromatosis]], [[Hurler syndrome]], [[mucopolysaccharidosis]], [[Noonan's syndrome]], [[pseudoxanthoma elasticum]], sarcomeric protein mutations, [[Werner's syndrome]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Hematologic''' | | '''Hematologic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[carcinoid syndrome|Carcinoid heart disease]], [[carcinoid syndrome]], [[carcinoid tumors]], [[Gaucher's disease]], [[hemochromatosis]], [[Hypereosinophilic syndrome]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Iatrogenic''' | | '''Iatrogenic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[radiotherapy|Postirradiation fibrosis]], [[Radiation]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Infectious Disease''' | | '''Infectious Disease''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Loeffler's syndrome]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Musculoskeletal/Orthopedic''' | | '''Musculoskeletal/Orthopedic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Hemochromatosis]], [[scleroderma]], [[systemic sclerosis]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 83: | Line 83: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Nutritional/Metabolic''' | | '''Nutritional/Metabolic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Alpha-L-iduronidase deficiency]], [[amyloidosis]], [[Anderson-Fabry disease]], [[cystinosis]], [[Fabry's disease]], fatty infiltration, [[Gaucher's disease]], [[generalized gangliosidosis GM1]], [[glycogen storage disease]], [[Hurler syndrome]], [[I-cell disease]], [[mucolipidosis II alpha/beta]], [[mucopolysaccharidosis]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 91: | Line 91: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Oncologic''' | | '''Oncologic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[carcinoid syndrome|Carcinoid heart disease]], [[carcinoid syndrome]], [[carcinoid tumors]], [[hypereosinophilic syndrome]], [[lymphoma]], [[malignancy]], [[metastasis|metastatic cancers]], [[paraneoplastic syndrome]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 103: | Line 103: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Psychiatric''' | | '''Psychiatric''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Hurler syndrome]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Pulmonary''' | | '''Pulmonary''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Churg-Strauss syndrome]], [[Loeffler's syndrome]], [[sarcoidosis]], [[scleroderma]], [[systemic sclerosis]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Renal/Electrolyte''' | | '''Renal/Electrolyte''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Scleroderma]], [[systemic sclerosis]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Rheumatology/Immunology/Allergy''' | | '''Rheumatology/Immunology/Allergy''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Amyloidosis]], [[cardiac amyloidosis]], [[Churg-Strauss syndrome]], [[Loeffler's syndrome]], [[paraneoplastic syndrome]], [[reactive arthritis]], [[sarcoidosis]], [[scleroderma]], [[systemic sclerosis]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Line 131: | Line 131: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Miscellaneous''' | | '''Miscellaneous''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Idiopathic]] | ||
|- | |- | ||
|} | |} |
Revision as of 05:04, 27 October 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Infiltrative cardiomyopathy; RCM
Overview
Restrictive cardiomyopathy is the least common cardiomyopathy. It is called this because it restricts the heart from stretching and filling with blood properly. Rhythmicity and contractility of the heart may be normal, but the stiff walls of the heart chambers (atria and ventricles) keep them from adequately filling. So blood flow is reduced, and blood that would normally enter the heart is backed up in the circulatory system. In time, restrictive cardiomyopathy patients develop heart failure.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Causes by Organ System
Causes in Alphabetical Order
Diagnosis
Electrocardiogram
Shown below is an example of restrictive cardiomyopathy with low voltage and flipped anterior T waves.